Financial Lp Hrt Sells 22,139 Shares of Clearmind Medicine (NASDAQ:CMND) Stock

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt sold 22,139 shares of Clearmind Medicine stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $3.31, for a total transaction of $73,280.09. Following the sale, the insider directly owned 81,353 shares in the company, valued at approximately $269,278.43. This trade represents a 21.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Monday, June 15th, Financial Lp Hrt sold 3,183 shares of Clearmind Medicine stock. The stock was sold at an average price of $3.32, for a total value of $10,567.56.
• On Friday, June 12th, Financial Lp Hrt sold 2,102 shares of Clearmind Medicine stock. The stock was sold at an average price of $3.36, for a total value of $7,062.72.
• On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The shares were sold at an average price of $0.12, for a total transaction of $27,022.92.
• On Wednesday, June 10th, Financial Lp Hrt acquired 2,159,052 shares of Clearmind Medicine stock. The stock was acquired at an average price of $0.15 per share, for a total transaction of $323,857.80.

Clearmind Medicine Stock Performance

NASDAQ CMND opened at $3.07 on Friday. The stock has a market cap of $3.13 million, a PE ratio of -0.02 and a beta of 0.64. Clearmind Medicine Inc. has a twelve month low of $2.10 and a twelve month high of $524.00. The stock has a fifty day simple moving average of $5.36 and a 200-day simple moving average of $14.74.

Clearmind Medicine (NASDAQ:CMND) last posted its earnings results on Monday, June 15th. The company reported ($6.78) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Clearmind Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.